A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
about
Nanomedicine and drug delivery strategies for treatment of inflammatory bowel diseaseReview article: anti-adhesion therapies for inflammatory bowel diseaseLeukocyte-endothelial cell adhesion: avenues for therapeutic interventionMapping of RNA accessible sites by extension of random oligonucleotide libraries with reverse transcriptase.Immune therapy in inflammatory bowel disease and models of colitis.Therapeutic effect of intracolonically administered nuclear factor kappa B (p65) antisense oligonucleotide on mouse dextran sulphate sodium (DSS)-induced colitis.Gene knockdown by large circular antisense for high-throughput functional genomics.A systematic review and meta-analysis of anti-adhesion molecule therapy in patients with active Crohn's disease.Correlation of toxicity and pharmacokinetic properties of a phosphorothioate oligonucleotide designed to inhibit ICAM-1.Molecules controlling lymphocyte migration to the gut.Mechanisms and consequences of phagocyte adhesion to endothelium.Medical options for treating Crohn's disease in adults: focus on antitumor necrosis factor-alpha chimeric monoclonal antibody.Fixing the intestinal mucosa in the bone marrow transplant patient: lessons from other intestinal immunodeficiencies and inflammatory disorders.Medical management of Crohn's disease.New insights into T cell biology and T cell-directed therapy for autoimmunity, inflammation, and immunosuppressionReview article: the management of severe Crohn's disease.Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis.New therapies in development for autoimmune diseases: their rationale for combination treatment.Vedolizumab for Crohn's disease.Immunotherapeutic approaches to inflammatory bowel diseases.Antisense approach to inflammatory bowel disease: prospects and challenges.A phase II dose ranging, double-blind, placebo-controlled study of alicaforsen enema in subjects with acute exacerbation of mild to moderate left-sided ulcerative colitis.Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease.New developments in the treatment of inflammatory bowel disease.Antiadhesion molecule therapy in inflammatory bowel disease.Review article: biological agents in the treatment of Crohn's disease.Codelivery of DNA and siRNA via arginine-rich PEI-based polyplexes.Role of cell adhesion molecules in leukocyte recruitment in the liver and gut.Adhesion molecules as therapeutic targets for autoimmune diseases and transplant rejection.Evaluation of new therapies for inflammatory bowel disease.Alpha 4 integrin blockade in inflammatory bowel disease.Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's diseaseEmerging biotherapies for inflammatory bowel disease.Antigen-specific blocking of CD4-specific immunological synapse formation using BPI and current therapies for autoimmune diseases.Recent developments in the pharmacological treatment of Crohn's disease.Novel biological strategies in inflammatory bowel diseases.Biologics in inflammatory bowel disease: how much progress have we made?Management of ulcerative colitis and Crohn's disease.Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.The vasculature and inflammatory bowel disease: contribution to pathogenesis and clinical pathology.
P2860
Q26777400-5AB8C366-2484-4C74-8021-F415424E7F0FQ26999705-555E86C9-32FE-48B8-A7AE-0BFBCCF7FFD6Q29544231-2883D049-D42C-4F33-B771-1500C274B10FQ30662658-49B53D09-8612-4F71-9585-0E65226F7E37Q30774968-35DFC849-460B-4D22-8A00-ACA5F28CBF78Q30856787-368712C7-4563-452E-808A-0201017FD2E6Q31168008-DC3E6BEF-0D30-4093-9089-90AFE0DC8419Q33514539-BD6FBA3D-B41D-4C33-9693-A4FBA343FC9BQ33657678-E73203F4-43A5-409D-9509-57FFE964A0EEQ33659442-C0E82D20-7D74-4086-9613-97BBA539DEC6Q33708657-E059038A-B834-4D47-AF16-2D14728CC30AQ33747158-087DB158-3A59-494A-8A2E-97FE214E28E6Q33788153-D86C8DDC-F9C0-43FE-AF5E-A032B8521911Q34046139-DA255E18-AA15-459E-903B-1BABFD205A47Q34175958-480F9D45-F132-4D3D-A1B1-265C902B433AQ34235823-70D1D915-129C-4BFA-9097-B0341617C7E6Q34243433-DFA20623-3CE0-4C67-BB84-3B2B526B6219Q34309745-CB122774-63A6-47F8-97D7-DFAD4D5C3BD6Q34326912-6B106E95-C033-4372-A9FD-66101001E802Q34451989-12ED0F46-1748-4CCC-BCE4-7BDF9475D65EQ34473572-D3C10339-2BD4-452F-A09D-AEC9D1299F4CQ34521106-554BA6E3-299F-4229-AE48-8795C2265FA2Q34527422-C74B4483-5697-4334-9BE5-966B6C6E118BQ34544666-C82F3373-46FC-482C-9DCA-2B57C4EF245DQ34752319-CFB7E930-8DEF-45B8-890E-A716C09E2777Q34799343-FFEFA7EB-9517-44C8-AC07-34389B630826Q35040420-0F0A7984-7238-437A-B8DA-C98E6C72B824Q35106847-27B05DFF-2E76-4AC7-8F93-A4EDDDDAED6AQ35116154-562AB43B-AC3A-4A32-9AD7-31D9311B63D1Q35216827-5F2FAD27-E85D-4AB7-9F6B-656356A900C1Q35553512-5D2C0A8A-2735-46E4-ABF8-FCD303E9CA94Q35594747-2D4EB5B1-71B9-4221-AD2A-8AACEE36DA76Q35602638-7EF95F8E-826E-4964-80FA-511624AA686CQ35637379-8D38E1F6-AC6F-4AF0-8A21-D99CD6EA56CDQ35753472-2E2638BC-90D8-4E6B-868C-33B5BB1B5A3EQ35787653-A31B9242-0C66-4912-A4AD-D24BF68B0165Q35861158-76188E4F-9115-4F65-89AF-9884790EA646Q36004867-276961B8-A01C-4D65-8202-AF7492ECA860Q36007709-99B54993-1AEE-40C6-82A8-EC8E80988F36Q36056593-BA047269-CD68-4C34-B068-A75DE3C9B4EA
P2860
A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
A placebo-controlled trial of ...... treatment of Crohn's disease.
@en
A placebo-controlled trial of ...... treatment of Crohn's disease.
@nl
type
label
A placebo-controlled trial of ...... treatment of Crohn's disease.
@en
A placebo-controlled trial of ...... treatment of Crohn's disease.
@nl
prefLabel
A placebo-controlled trial of ...... treatment of Crohn's disease.
@en
A placebo-controlled trial of ...... treatment of Crohn's disease.
@nl
P2093
P1433
P1476
A placebo-controlled trial of ...... treatment of Crohn's disease.
@en
P2093
Bennett CF
Bowen-Yacyshyn MB
Shanahan WR Jr
Yacyshyn BR
P304
P356
10.1016/S0016-5085(98)70418-4
P407
P577
1998-06-01T00:00:00Z